UNASSIGNED: Objectives. Chemotherapy as first-/second-line treatment in different @entity470 ( @entity470 ) mutation @entity2220 remains controversial. Methods. Consecutive @entity1 were collected between 2009 and 2012. @entity1 were divided into two groups (1st-line chemotherapy: n = 56 and 2nd-line chemotherapy: n = 55). Their outcomes profiles were analyzed. Results. The @entity1349 ( @entity1349 ) of all @entity1 (390 versus 662 days, p < 0.0001), as well as both progression-free survival (PFS, 151 versus 252 days, p = 0.0001) and @entity1349 (308 versus 704 days, p = 0.0001) of @entity1 with @entity9512 mutation (n = 63), who received 2nd-line chemotherapy, was significantly poor. By univariate and multivariate analysis, 2nd-line chemotherapy, and @entity9512 mutation were significantly related to poor PFS and @entity1349 . Conclusion. In advanced @entity2220 , @entity9512 mutation and 2nd-line chemotherapy caused a poor outcome. It is a consideration to choice of 1st-line chemotherapy in these subjects. A prospective design is warranted to confirm this finding.

The Impact of Sequence of Chemotherapy and @entity470 -TKI Treatment on Different XXXX Mutation @entity2220 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity9512 :: ('p|SUB|L|858|R', 'ProteinMutation') :: ['L858R'] @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity470 :: (1956,Gene) :: ['EGFR']
